Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

Jakob Anninga, R. Maarten Egeler(Leiden University Medical Center), Pancras C.W. Hogendoorn(Leiden University Medical Center), Hans Gelderblom(Leiden University Medical Center), A. H. M. Taminiau(Leiden University Medical Center), Judith R. Kroep, Marta Fiocco(Leiden University Medical Center)
European Journal of Cancer
June 25, 2011
10.1016/j.ejca.2011.05.030
Cited by 464

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k